Sign In
Buy CDNA
$38.37
-1.36 (-3.42%)
At Close: Jul 20, 2026
CareDx (CDNA) Reports Q1 Loss, Tops Revenue Estimates
06:48pm, Thursday, 05'th May 2022
CareDx (CDNA) delivered earnings and revenue surprises of -225% and 1%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
These Charts Explain Why I'm Holding This Healthcare Company
11:05am, Friday, 29'th Apr 2022 The Motley Fool
Transplants are in high demand; this company is making the process of getting one smoother.
These Charts Explain Why I'm Holding This Healthcare Company
07:05am, Friday, 29'th Apr 2022
Transplants are in high demand; this company is making the process of getting one smoother.
CareDx Congratulates Board Member Dr. Hannah Valantine on ISHLT Lifetime Achievement Award
02:45pm, Thursday, 28'th Apr 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically d
CareDx to Report First Quarter 2022 Financial Results
04:01pm, Wednesday, 27'th Apr 2022
SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically dif
International Society for Heart and Lung Transplantation Foundation Selects Reg Seeto as Corporate Chair
01:15pm, Wednesday, 27'th Apr 2022 GlobeNewswire Inc.
CareDx CEO and President, Reg Seeto, Joins ISHLT Foundation Global Steering Committee Focused on Driving Innovations for Heart and Lung Transplant Patients CareDx CEO and President, Reg Seeto, Joins I
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
02:07pm, Monday, 25'th Apr 2022 Benzinga
Upgrades
RBC Capital upgraded the previous rating for United States Steel Corp (NYSE:X) from Sector Perform to Outperform. United States Steel earned $3.64 in the fourth quarter, compared to $0.27 in
CareDx Demonstrates Potential of AlloHeme and AlloCell for Allogeneic Cell Transplant and Therapy Monitoring at Transplantation & Cellular Therapy Meetings
11:00am, Friday, 22'nd Apr 2022 GlobeNewswire Inc.
CareDx Announces that OTTR Patient Management Software Now Validated for SMART on FHIR CareDx Announces that OTTR Patient Management Software Now Validated for SMART on FHIR
CareDx Supports UC Davis Health Pluralist Program Aimed at Reducing Health Disparities in Organ Transplantation
11:10am, Thursday, 21'st Apr 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically d
CareDx Showcases Leadership with Over 25 Oral Presentations and Posters at the International Society for Heart and Lung Transplantation Meeting
11:00am, Wednesday, 20'th Apr 2022 GlobeNewswire Inc.
Data Highlights Clinical Utility of CareDx Solutions, Including Findings from Surveillance HeartCare Outcomes Registry (SHORE) Demonstrating Power of Multimodality Assessment for More Precise Interven
CareDx Reports Over 200,000 Heart Transplant Patient Results Served
11:41am, Thursday, 14'th Apr 2022 GlobeNewswire Inc.
CareDx Testing Services Have Been Used in Over 30,000 Heart Transplant Patients and Over 90 Percent of Centers in the United States CareDx Testing Services Have Been Used in Over 30,000 Heart Transpla
CareDx to Host Symposium at CEoT Featuring the Latest Multimodality Innovations in Kidney and Lung Transplant Surveillance
11:00am, Wednesday, 06'th Apr 2022 GlobeNewswire Inc.
Symposium, “Improved Precision with a Multimodality Approach,” Reviews Innovative Solutions for a More Holistic View of Allograft Health Symposium, “Improved Precision with a Multimodality Appro
CareDx Partners with the European Society for Organ Transplantation to Provide Clinical Evidence Supporting the Use of AlloSeq cfDNA with European Transplant Healthcare Professionals
11:00am, Wednesday, 30'th Mar 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically d
CareDx’s AlloCare App Now Integrated with TxAccess to Help Pre-Transplant Patients Navigate the Waitlist Process
11:00am, Thursday, 24'th Mar 2022 GlobeNewswire Inc.
New Features Aim to Help More Patients with Kidney Failure Receive an Organ Transplant New Features Aim to Help More Patients with Kidney Failure Receive an Organ Transplant
UPDATE -- CareDx Wins $44.9M in Damages in False Advertising Trial Against Natera; Natera Intentionally Deceived Transplant Community
10:00am, Wednesday, 23'rd Mar 2022 GlobeNewswire Inc.
Jury Finds Natera Falsely Advertised its Prospera Kidney Transplant Technology Jury Finds Natera Falsely Advertised its Prospera Kidney Transplant Technology
